William Blair Has Positive Forecast for SPRY FY2024 Earnings

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) – Analysts at William Blair upped their FY2024 earnings estimates for ARS Pharmaceuticals in a report released on Monday, November 4th. William Blair analyst L. Hanbury-Brown now anticipates that the company will post earnings of ($0.63) per share for the year, up from their previous forecast of ($0.68). William Blair currently has a “Strong-Buy” rating on the stock. The consensus estimate for ARS Pharmaceuticals’ current full-year earnings is ($0.66) per share. William Blair also issued estimates for ARS Pharmaceuticals’ Q4 2024 earnings at ($0.20) EPS, Q1 2025 earnings at ($0.18) EPS, Q2 2025 earnings at ($0.07) EPS, Q3 2025 earnings at $0.04 EPS, Q4 2025 earnings at $0.02 EPS and FY2025 earnings at ($0.19) EPS.

ARS Pharmaceuticals (NASDAQ:SPRY) last issued its quarterly earnings data on Tuesday, August 6th. The company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.01). The company had revenue of $0.50 million for the quarter, compared to the consensus estimate of $2.00 million.

Other equities analysts also recently issued research reports about the stock. Raymond James raised shares of ARS Pharmaceuticals from an “outperform” rating to a “strong-buy” rating and boosted their target price for the stock from $18.00 to $22.00 in a report on Tuesday, August 13th. Leerink Partners increased their price objective on shares of ARS Pharmaceuticals from $21.00 to $25.00 and gave the company an “outperform” rating in a report on Friday, September 20th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $30.00 target price on shares of ARS Pharmaceuticals in a research report on Tuesday, October 8th. Four analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $24.00.

ARS Pharmaceuticals Trading Up 2.6 %

SPRY opened at $15.72 on Wednesday. The firm’s 50 day simple moving average is $14.12 and its two-hundred day simple moving average is $11.34. ARS Pharmaceuticals has a 1-year low of $3.38 and a 1-year high of $17.08.

Insiders Place Their Bets

In other ARS Pharmaceuticals news, COO Brian Dorsey sold 50,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 20th. The stock was sold at an average price of $15.00, for a total value of $750,000.00. Following the sale, the chief operating officer now owns 6,024 shares in the company, valued at approximately $90,360. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. In related news, CEO Richard E. Lowenthal sold 100,000 shares of the business’s stock in a transaction on Tuesday, August 20th. The shares were sold at an average price of $15.03, for a total value of $1,503,000.00. Following the completion of the sale, the chief executive officer now owns 1,497,447 shares of the company’s stock, valued at approximately $22,506,628.41. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Brian Dorsey sold 50,000 shares of the company’s stock in a transaction on Tuesday, August 20th. The stock was sold at an average price of $15.00, for a total transaction of $750,000.00. Following the transaction, the chief operating officer now owns 6,024 shares of the company’s stock, valued at $90,360. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 1,055,895 shares of company stock valued at $14,619,032. Company insiders own 40.10% of the company’s stock.

Institutional Investors Weigh In On ARS Pharmaceuticals

A number of large investors have recently modified their holdings of the business. Royce & Associates LP lifted its position in ARS Pharmaceuticals by 7.1% during the third quarter. Royce & Associates LP now owns 691,455 shares of the company’s stock worth $10,026,000 after buying an additional 45,755 shares in the last quarter. GSA Capital Partners LLP raised its holdings in shares of ARS Pharmaceuticals by 67.7% during the 3rd quarter. GSA Capital Partners LLP now owns 98,900 shares of the company’s stock worth $1,434,000 after acquiring an additional 39,921 shares during the period. US Bancorp DE boosted its position in shares of ARS Pharmaceuticals by 11,951.6% during the 3rd quarter. US Bancorp DE now owns 18,680 shares of the company’s stock valued at $271,000 after acquiring an additional 18,525 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its holdings in shares of ARS Pharmaceuticals by 63.8% in the third quarter. China Universal Asset Management Co. Ltd. now owns 18,645 shares of the company’s stock valued at $270,000 after purchasing an additional 7,262 shares during the period. Finally, J.W. Cole Advisors Inc. increased its position in ARS Pharmaceuticals by 33.2% during the third quarter. J.W. Cole Advisors Inc. now owns 20,520 shares of the company’s stock worth $298,000 after purchasing an additional 5,120 shares during the last quarter. Hedge funds and other institutional investors own 68.16% of the company’s stock.

ARS Pharmaceuticals Company Profile

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.